scholarly journals From the Editor: A Personal Coda

2010 ◽  
Vol 19 (4) ◽  
pp. 430-431
Author(s):  
THOMASINE KUSHNER
Keyword(s):  
New York ◽  
San Francisco ◽  
Medical Center ◽  
Special Section ◽  
Human Values ◽  
Cambridge University ◽  
Bioethics Education ◽  
The Press ◽  
The Future ◽  
Education Needs

The Cambridge Consortium for Bioethics Education took place at the Cambridge University Press offices in New York this April. Hosted and sponsored by the Press, with cosponsors, CQ and the Program in Medicine & Human Values at California Pacific Medical Center in San Francisco, the Consortium brought together representative leaders in bioethics to discuss some of the unsolved issues in the field: goals, curriculum, methods, and assessment. For three days participants shared their own programs, research, and current projects as well as ideas on where bioethics education needs to go in the future. Beginning with this special section, and in CQ’s Bioethics Education section in subsequent volumes, we will be bringing you what is happening as bioethicists everywhere take a more focused approach to the field.

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

2004 ◽  
Vol 126 (1) ◽  
pp. 91-101 ◽  
Author(s):  
Marion G. Peters ◽  
H.W. Hann ◽  
Paul Martin ◽  
E.Jenny Heathcote ◽  
P. Buggisch ◽  
...  
Keyword(s):  
New York ◽  
Los Angeles ◽  
San Francisco ◽  
Adefovir Dipivoxil ◽  
Medical Center ◽  
Jefferson Medical College ◽  
Toronto Western Hospital ◽  
Medical College ◽  
Centre Hospitalier ◽  
Centre Hospitalier Universitaire
Sign in / Sign up

Export Citation Format

Share Document